Tvardi <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Approves New Severance and Retention Compensation Plan for Executives
Tvardi Therapeutics Inc. has approved a one-time retention compensation package for its named executive officers. Chief Executive Officer Dr. Imran Alibhai received an option to purchase 47,500 shares, while Chief Medical Officer Dr. John Kauh and Chief Financial Officer Dan Conn each received options for 17,500 shares. The options have an exercise price based on the closing per-share price on the grant date, with 25% of the shares vesting on the one-year anniversary of December 16, 2026, and the remainder vesting in equal monthly installments over the next three years. Additionally, the company adopted a Severance and Change in Control Plan providing severance and equity vesting acceleration benefits to eligible employees, including the named executive officers, in the event of certain qualifying terminations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-122615), on December 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.